What Surgicel Treats: Main Uses and Benefits

The use of Surgicel is aligned with its official indication to help manage symptoms related to physical discomfort during procedures. The official indication is applied in clinical settings that involve acute or unstable symptom patterns, such as those related to capillary, venous, and small arterial bleeding.

This material is commonly used to help with acute, physical blood loss, which are symptoms that create noticeable physiological strain. This capability helps support the overall goal of controlling blood loss, which contributes to easing the overall symptom load and supports the patient during difficult episodes by assisting with temporary stabilization. This supportive function is relevant in contexts where short-term symptomatic assistance is needed.

Its property of natural breakdown supports the patient by providing a temporary solution that assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning Surgicel is commonly used to help with acute symptomatic episodes, offering temporary support when symptoms create noticeable physiological strain.

Surgicel (oxidized regenerated cellulose) is regulated as an adjunctive hemostatic medical device, meaning its eligibility rules are based on the surgical site and type of bleeding, not typically on the patient's systemic health or age.

Eligibility Scope

Category	Regulatory Statement
Use Allowed for	Control of capillary, venous, and small arterial hemorrhage.
Use Contraindicated	Controlling hemorrhage from large arteries or large defects in arteries or veins; implantation in bone defects (e.g., fractures); use as an adhesion prevention product.
Age-Related Rules	No specific minimum age restriction is documented as an absolute contraindication in official labeling.
Systemic Conditions	Eligibility is not restricted based on hepatic impairment, renal impairment, pregnancy, or lactation.
Conditional Use	When used near the spinal cord, optic nerve, or areas of bony confine, the material must always be removed after hemostasis is achieved to prevent swelling and pressure.

---

Eligibility Classifications (High-Level)

Classification	Definition in Regulatory Documents
Eligibility Severity	Contraindicated for large-vessel bleeding and bone implantation; Conditional Use for application near critical neural structures.
Context Constraints	Anatomical (removal required from bony confines) and Procedural (not to be left in contaminated wounds without drainage).

---

Resulting Eligibility Structure

Official eligibility statements:

• Contraindicated for controlling hemorrhage from large arteries or large defects in veins.
• Contraindicated for implantation in bone defects and use on non-hemorrhagic serous oozing surfaces.
• Must always be removed when used near the spinal cord, optic nerve, or areas of bony confine after bleeding has stopped.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define the product's eligibility based on preventing physical complications at the surgical site. The primary restrictions involve preventing use in contexts where it would be ineffective (large vessel bleeding) or where its post-application swelling could cause harm if left in place (neural structures and bone). Eligibility is not defined by systemic patient factors like age or organ function.

The interaction profile for Surgicel (Oxidized Regenerated Cellulose, ORC) is determined by its classification as an adjunctive, topically applied medical device rather than a systemic medicinal product. Consequently, its regulatory labeling strictly addresses local compatibility, and does not document any systemic pharmacokinetic (PK) or pharmacodynamic (PD) interactions with oral or intravenous medicinal products.

Interaction Scope

Property	Official Regulatory Documentation Statement
Systemic PK/PD Interactions	None documented. No official documentation for CYP- or transporter-mediated interactions or systemic pharmacodynamic effects is cited.
Timing/Population Notes	No systemic timing rules or population-specific interaction cautions are documented in the official interaction profile.
Interaction-Related Restrictions	Must not be impregnated with anti-infective agents, buffering substances, or other hemostatic substances.

The official constraints are exclusively local restrictions on co-administration at the surgical site, established within the official labeling. These statements prohibit the physical mixing of the device with the listed substance categories prior to or during application. This prohibition represents a procedural constraint required by the regulatory basis, which determines the product's entire interaction structure.

The mechanism of Surgicel (Oxidized Regenerated Cellulose, ORC) is defined by its immediate, localized interaction with the elements of blood, relying on physicochemical principles rather than traditional systemic pharmacology.

Physical Barrier and Scaffolding Mechanism

This domain covers the material's rapid absorption of blood fluid and subsequent physical transformation into a tenacious gelatinous coagulum. This process immediately acts as a mechanical barrier to blood flow while simultaneously creating a structured surface for the essential adhesion and aggregation of platelets, concentrating cellular components to support the initiation of the primary hemostatic response.

Acid-Mediated Coagulum Stabilization

This chemical domain addresses the presence of carboxylic acid groups within the oxidized cellulose, which creates a localized acidic microenvironment (low pH) at the application site. This chemical shift reinforces the structural integrity of the hemostatic coagulum, contributing to the structural stability of the hemostatic coagulum, and the low pH environment inhibits the proliferation of local bacteria. This purely local action means the material supports clot formation but does not engage the systemic pathways required to modulate or address systemic coagulation pathway deficiencies.

Surgicel, an oxidized regenerated cellulose (ORC) material, is designated for topical and local application during surgical procedures. Its administration is based on application principles rather than systemic dosing, as it is classified as a medical device. The available forms include a knitted fabric, a non-woven sponge, and a fine powder, the latter of which may be applied endoscopically using a specialized applicator.

The fundamental principle of use is to apply only the minimum amount of material necessary to cover the bleeding site. Once hemostasis is achieved, the removal of any excess material is required before the surgical site is closed. Crucially, the material is ready for immediate use and must not be moistened with saline or water, nor should it be combined with other substances like thrombin or anti-infective agents, to maintain its intended properties.

While the material is designed to be fully bioabsorbed by the body within approximately 7 to 14 days, a specific and critical instruction requires that the material must always be removed when used near confined structures, such as the spinal cord or optic nerve/chiasm. This focus on careful quantity management and site-specific removal defines the procedural structure for the product's use.

Surgicel: Recent Clinical Evidence

Research for oxidized regenerated cellulose (ORC) products, often used in surgery, was studied for its application as an adjunctive material in the context of localized bleeding. The studies available are used by regulatory bodies, such as the FDA, to understand the data collected when the material is used alongside standard surgical techniques.

Evidence for Use in Controlling Capillary, Venous, and Small Arterial Bleeding

Research examining this indication explored observations related to bleeding cessation from tissue surfaces, such as capillary, venous, and small arterial hemorrhage, when standard methods like stitching or heat application are not practical. The research included short-term Randomized Controlled Trials (RCTs) and prospective, single-arm multicenter studies. The studies monitored key short-term outcomes related to physiological strain, primarily measuring the Time to Hemostasis (TTH) and the overall Hemostatic Success Rate observed at the target site. Studies reported measurements of TTH and documented patterns where a high proportion of sites demonstrated cessation of detectable bleeding within the specific, short observation window (usually under 10 minutes).

Research on Different ORC Formulations and Comparators

The available evidence explored what was observed when different physical forms of the material, such as the fine powder form compared to the knitted fabric, were used across various surgical environments. Comparative studies explored what was observed when the ORC product was used against other materials that are also studied to help with bleeding. Research describes data show patterns related to the TTH measurements across the different materials studied, which contributes to the broader evidence landscape regarding comparative observations.

Long-Term Follow-up and Material Absorption Studies

Studies conducted to support regulatory findings primarily research the short-term outcomes observed immediately following the procedure. Post-operative follow-up research often extended up to 30 days to observe study outcomes. However, long-term outcomes are not well characterized. Research describes data show patterns related to the process of bioabsorption—how the body naturally breaks down and absorbs the material—but long-term functional outcomes were not the primary focus of the existing controlled trials.

Evidence in Specific Surgical and Patient Groups

The research evidence mainly was observed in adult subjects (aged 18 and older) across a wide range of surgical disciplines, including General, Gynecological, and Cardiothoracic surgery. The results apply only to the populations studied. Evidence is limited in several groups, as certain patient populations, such as those with highly complex conditions or pediatric patients, were often excluded from the main regulatory clinical trials. Data for these groups remain insufficient, meaning there is limited information on outcomes in these populations.

Key Evidence Gaps and Areas of Uncertainty

The body of research contains areas of uncertainty. A key limitation is that follow-up durations were limited, meaning the primary evidence focuses on immediate surgical observation rather than long-term outcomes or recovery. Furthermore, studies have mainly focused on mild to moderate bleeding, meaning the research has not broadly examined outcomes of ORC materials in the context of high-pressure or large-volume hemorrhage. Research is ongoing in post-market settings, and data are still emerging in certain specialized surgical contexts.

Common questions about Surgicel (FAQ)

---

Q: How safe is Surgicel for use in children, and are there official warnings about this population?

Official product information indicates that the data available from main regulatory clinical trials is limited for pediatric patients. This is because children were often excluded from these studies. Therefore, information regarding outcomes in this population relies on clinical judgment rather than comprehensive trial evidence specific to this age group.

---

Q: Are there any long-term effects of having Surgicel implanted?

Studies submitted to regulatory bodies focus primarily on the short-term goal of achieving hemostasis during surgery. Long-term outcomes for patients with Surgicel implanted are generally not well characterized in these reports due to the limited follow-up duration of the trials.

---

Q: How does Surgicel compare to topical thrombin products?

Official labeling states that Surgicel must not be moistened with, or combined with, topical thrombin or anti-infective agents. This is because the acidic nature of the device has been shown in studies to destroy the hemostatic activity of thrombin.

---

Q: Are there any documented cases of long-term complications with Surgicel?

Regulatory warnings describe the risk of serious complications, which are primarily related to the physical presence of the device. These include the documented risk of complications such as nerve damage, paralysis, or blindness if the material is left in or migrates to areas where it can exert pressure on critical neural structures.

---

Q: What is the relationship between Surgicel and blood clotting factors?

The device's hemostatic action relies on a localized, physical and chemical mechanism to accelerate clot formation. Official information indicates that this action aids in clot formation even without altering the patient’s normal systemic coagulation mechanism (the body’s blood clotting factors).

---

Q: Is it normal to have some drainage where Surgicel was used?

Official procedural instructions caution against closing the device in a contaminated wound without appropriate drainage management. This regulatory instruction highlights that the presence and management of drainage is considered when the product is used in certain surgical settings.

---

Q: What is the difference between Surgicel Fibrillar and Surgicel Original?

Surgicel Fibrillar is a specific physical form of oxidized regenerated cellulose. Regulatory submissions noted that this form achieved a more rapid time to hemostasis and was observed to have enhanced adherence to irregular bleeding surfaces when compared to the Original knitted material.

---

Q: Is it possible for Surgicel to show up on an X-ray or CT scan?

Official product precautions indicate that retained excess material can cause a foreign body reaction. This reaction has the potential to mimic or cause artifacts on radiographic images, which may lead to diagnostic interpretation errors.

---

Q: Is Surgicel intended for dental procedures, like extractions?

Yes, the official labeling for this product includes an indication for its use as an adjunctive material to help control bleeding specifically in the context of exodontia (tooth extractions) and various oral surgery procedures.

---

Q: Is Surgicel a product that requires a prescription?

As a surgical medical device subject to regulatory review, its sale and application are restricted to use by or on the order of a licensed physician or qualified practitioner. This is the official requirement for its proper distribution and use in a clinical setting.

---

Q: Does Surgicel have a specific shelf life or expiration date?

Yes, official product specifications confirm that the product is assigned a specific shelf life, which can vary by the specific form (e.g., up to five years for some forms). The device must also be stored at a controlled room temperature to maintain its sterility and integrity.

---

Q: Does the use of Surgicel affect future surgeries in the same area?

One potential complication listed in official adverse event reports is the formation of adhesions at the surgical site. Adhesions are bands of scar tissue that can potentially affect the surgical area during any subsequent procedures.

---

Q: Can Surgicel be used in patients with bleeding disorders?

The hemostatic action works through a localized physical mechanism, and regulatory information indicates that it is designed to assist in clot formation even without altering the patient’s normal systemic coagulation mechanism.

---

Q: Can the material in Surgicel migrate from the placement site?

Official warnings explicitly state that if the material is not removed before the surgical site is closed, it can potentially migrate from the original application site. This potential for movement is specifically addressed in the procedural instructions for use.

Storage Requirements

Surgicel Absorbable Hemostats and Powder must be stored at controlled room temperature, typically defined as 15 C to 30 C (59 F to 86 F). The product is supplied sterile and must be kept in its original, undamaged packaging to maintain its sterile barrier. The product is not compatible with resterilization methods and must not be reused.

Handling and Stability

The official labeling notes that a slight discoloration may occur with age, but this change does not affect the hemostat’s performance. The material should be applied dry and should not be moistened for storage.

Disposal Instructions

As a single-use sterile device, the used material, any unused portions, or damaged devices must be discarded. Disposal must be carried out according to accepted medical practice and all applicable national, local, or institutional guidelines concerning biohazardous materials and waste.